Home > Clinics and Services > Clinics and Departments > Pediatric Oncology > Experimental Therapeutics in Pediatric Cancer
Pediatric Oncology Experimental Therapeutics in Pediatric Cancer

US News and World Report Ranking Badge
Pediatric Oncology Experimental Therapeutics in Pediatric Cancer

Experimental Therapeutics in Pediatric Cancer


The Experimental Therapeutics in Pediatric Cancer program makes clinical trials available to your child when traditional cancer therapies have not been successful.

We are the only pediatric hospital in the region that provides access to cancer clinical trials, which means your child can benefit from the latest innovations in research while staying close to home. This is important because family connection and familiarity with surroundings has been shown to improve the success of cancer treatment.

What is Experimental Therapeutics?

Our trials test treatment methods that have not yet been used for your child’s diagnosis. Many medications involved in clinical trials have been proven effective and safe for other cancers or for use in adult patients, but not specifically for pediatric cancer. Experimental Therapeutics is the science of taking those treatments and trialing them with different cancers to test their effectiveness.

What are the Phases of a Cancer Research Trial?

Phase 1: A test of a drug to determine its safety and proper dosage for pediatric patients. At this phase, we do not know yet if a drug is effective.

Phase 2: This phase comes after a drug’s safety has been proven and tests the drug’s effectiveness.

Phase 3: This phase ensures a drug meets our standard of care. Phase 3 is designed to verify if a drug can improve on how we currently treat a diagnosis. 

Financial Assistance to Help Fund Your Trial Participation

If your child qualifies for a clinical trial in our program, we provide guidance in finding financial resources to help cover the cost of the trial. In addition to working with Missouri and Kansas Medicaid programs, we also assist with access to Medicaid programs in other states. Many parts of the clinical trial’s process, such as labs, X-rays, and other essentials tests, are covered by your health insurance. 

Our Research Team

The Experimental Therapeutics Research Team works to provide the best in cancer research expertise while providing the emotional support your family needs. Our team includes four doctors, one nurse practitioner, four research coordinators, and one social worker. Learn more about the Hematology, Oncology, and Bone Marrow Transplant team at Children’s Mercy.

Physicians


Jaszianne A Tolbert, MD
Assistant Professor of Pediatrics
Director, Experimental Therapeutics in Pediatric Cancer Program
Division of Hematology/Oncology/Bone Marrow Transplantation
Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation

Keith August, MD, MS
Associate Professor of Pediatrics
Director, Leukemia & Lymphoma Program
Division of Hematology/Oncology/Bone Marrow Transplantation

Katherine Chastain, MD
Assistant Professor of Pediatrics
Director, Sarcoma Program
Division of Hematology/Oncology/Bone Marrow Transplantation

Kevin Ginn, MD
Assistant Professor of Pediatrics
Director, Pediatric Brain Tumor Program
Division of Hematology/Oncology/Bone Marrow Transplantation

Nurse Practitioner

Allison Rees, MSN, RN, CPNP-AC
Division of Hematology/Oncology/Bone Marrow Transplantation

Clinical Research Coordinators


Jami Wierson, RN, BSN, MBA, CCRC
Research Coordinator Manager
Division of Hematology/Oncology/Bone Marrow Transplantation

Amber Jenkins, MSc, CCRC
Division of Hematology/Oncology/Bone Marrow Transplantation

Chasity Runyan, CCRP
Division of Hematology/Oncology/Bone Marrow Transplantation

Social Work

Caroline Gill, MSW, LMSW, LCSW
Division of Hematology/Oncology/Bone Marrow Transplantation

Investigational Drug Service (IDS) Pharmacy

The Children’s Mercy IDS Pharmacy is a full service pharmacy providing clinical knowledge and operational support for all studies involving investigational drugs at Children’s Mercy. As part of the Experimental Therapeutics Team, the IDS Pharmacy staff provides protocol and sponsor directed security, accountability, education, and dispensing of all Investigational as well as ancillary medications.

Cancer Trials Currently Available

This list changes frequently and does not include most of our Children’s Oncology Group trials.

For more information about current available trials please contact us.

Treatment Area Study Name
Acute Lymphoblastic Leukemia AALL1521: A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic Leukemia
Refractory Solid Tumors ADVL1322: A Phase 2 Study of Pazopanib in Children, Adolescents, and Young Adults with Refractory Solid Tumors
Relapsed/Refractory Juvenile Myelomonocytic Leukemia ADVL1521: Phase 2 Study of the MEK inhibitor Trametinib in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Refractory Solid Tumors  ADVL1622: A Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Relapsed/Refractory Classic Hodgkin Lymphoma AHOD1721: A Phase 2 trial of nivolumab + brentuximab vedotin for children, adolescents, and young adults with relapsed/refractory CD30 + classic Hodgkin lymphoma after failure of first-line therapy, followed by brentuximab +bendamustine for participants with a suboptimal response.
Anaplastic Large Cell Lymphoma ANHL12P1: A Randomized Phase 2 Trial of Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma
Recurrent/Refractory Solid Tumors APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Recurrent/Refractory Solid Tumors APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions
Recurrent/Refractory Solid Tumors APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations.
Recurrent/Refractory Solid Tumors APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Tazemetostat for Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex
Recurrent/Refractory Solid Tumors APEC1621D: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of LY3023414 in Solid Tumors
Recurrent/Refractory Solid Tumors APEC1621E: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Selumetinib in Patients with Tumors Harboring Activating MAPK Pathway Mutations
Recurrent/Refractory Solid Tumors APEC1621F: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations
Recurrent/Refractory Solid Tumors APEC1621G: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Actionable BRAF V600 Mutations
Recurrent/Refractory Solid Tumors APEC1621H: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes
Relapsed/Refractory Solid Tumors  APEC1621I: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
BRAF V600 Mutation Positive Relapsed/Refractory High Grade Glioma (HGG) CDRB436G2201: Phase 2 Open-Label Global Study to Evaluate the Effect of Dabrafenib in Combination with Trametinib in Children and Adolescent Patients with BRAF V600 Mutation Positive Relapsed or Refractory High Grade Glioma (HGG)
Relapsed/Refractory Neuroblastoma or Medulloblastoma V0706: A Phase 2 Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma
Neuroblastoma in Remission NMTRC014: Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
Relapsed/Refractory Solid Tumors or CNS tumors AflacST1502: A Phase 2 Study of Sirolimus in Combination with Metronomic Chemotherapy in Children with Recurrent and/or Refractory Solid and CNS Tumors
Relapsed/Refractory Solid Tumors I5B-MC-JGDN: A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors

 

Copyright © 2018 The Children’s Mercy Hospital